Elevating the Future of Cancer care with Alpha Theranostics

Project Information

Accelerate.EU

Grant agreement ID: 101173001

DOI

10.3030/101173001

EC signature date 11 September 2024

Start date 1 October 2024

End date 30 September 2029

Funded under

• Health

Total cost

€ 16 115 520,00

EU contribution

€ 8 007 322,50

Coordinated by

ASSOCIATION HOSPITALIERE DE BRUXELLES-CENTRE HOSPITALIER UNIVERSITAIRE JULES BORDET
Belgium

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Publications

Peer reviewed articles (3)

An ²¹¹At-labeled Tetrazine for Pretargeted Therapy

Author(s): Matthias M. Herth, Lars Hvass, Christian B. M. Poulie, Marius Müller, Rocio García-Vázquez, Tobias Gustavsson, Vladimir Shalgunov, Anne S. Clausen, Jesper T. Jørgensen, Ellinor Hansson, Holger Jensen, Emma Aneheim, Sture Lindegren, Andreas Kjaer, Umberto M. Battisti
Published in: Journal of Medicinal Chemistry, Issue 68, 2025, ISSN 0022-2623
Publisher: American Chemical Society (ACS)
DOI: 10.1021/ACS.JMEDCHEM.4C02281

Recent advances in understanding and improving the stability of 211At-radiopharmaceuticals

Author(s): Romain Fouinneteau, Nicolas Galland, Cécile Perrio, François Guérard
Published in: Nuclear Medicine and Biology, 2025, ISSN 0969-8051
Publisher: Elsevier BV
DOI: 10.1016/J.NUCMEDBIO.2025.109573

The molecular blueprint of targeted radionuclide therapy

Author(s): Irina Primac, Kevin Tabury, Alpaslan Tasdogan, Sarah Baatout, Ken Herrmann
Published in: Nature Reviews Clinical Oncology, Issue 22, 2025, ISSN 1759-4774
Publisher: Springer Science and Business Media LLC
DOI: 10.1038/S41571-025-01069-Z